The Six-Month Surgery Window
Between filing a Draft Red Herring Prospectus (DRHP) and ringing the NSE bell, something extraordinary is happening to Indian startups. According to regulatory filings from the past week, at least 12 of the 23 companies in Inc42’s updated IPO tracker have made material business model changes during the review process—not before it. This isn’t cosmetic. We’re witnessing real-time strategic amputations: Zepto shutting down its B2B vertical, OfBusiness divesting its international operations, and multiple fintech players exiting lending businesses they spent years building.
The catalyst? SEBI’s increasingly strict interpretation of profitability requirements for tech IPOs, combined with volatile public market conditions that have caused three high-profile IPO postponements in April 2026 alone. The regulatory body now requires not just one quarter of profitability, but demonstrable “sustainable unit economics” across core segments—language that didn’t exist in 2024 guidelines.
The Anatomy of a DRHP Pivot
PharmEasy’s playbook offers the clearest example. After filing its third DRHP attempt in late March 2026, the healthtech giant quietly wound down its 18-month-old telemedicine service and diagnostic equipment rental business within weeks. Combined, these segments represented 22% of revenue but operated at -67% contribution margins. The April 30 amendment filing showed adjusted EBITDA swinging from -₹340 crore to +₹180 crore—purely through subtraction.
Investment banker sources (speaking anonymously due to deal sensitivity) confirm this is now standard practice: “The DRHP review period has become a negotiation. SEBI queries force companies to prove each revenue stream can stand alone profitably. If it can’t, it gets cut. We’re essentially doing PE-style operational restructuring, but on a public timeline.”
The numbers tell the story:
- Average time from DRHP filing to approval has stretched from 68 days (2024) to 147 days (2026 YTD)
- 31% of 2026 DRHP amendments involve “discontinuation of business segments”
- Median EBITDA margin improvement during review period: 890 basis points
- Employee headcount reductions during DRHP review: averaging 18% across the tracker cohort
Cross-Domain Shockwaves: What Gets Left Behind
This surgical precision creates orphaned markets and ecosystems. When Swiggy divested its hyperlocal grocery delivery in tier-3 cities (disclosed in a May 1 filing), it wasn’t just exiting unprofitable zip codes—it stranded the 2,400+ dark store operators and delivery partners who had built livelihoods around that infrastructure. These aren’t layoffs that appear in restructuring headlines; they’re ecosystem collapses that happen in footnotes.
For global investors, the implications ripple outward:
-
Geographic Retrenchment → At least 5 IPO candidates have exited Southeast Asian expansion plans initiated 2023-2024. The “India stack, global ambition” narrative is reversing to “India depth, geographic focus.” This matters for LPs in Tiger Global, Sequoia India funds that priced in regional expansion multiples.
-
Vertical SaaS Compression → B2B SaaS startups are abandoning multi-product strategies. Zoho competitors that built HR, CRM, and accounting modules are now pure-play solutions. The dream of Indian horizontal platforms is colliding with the reality of SEBI’s segment-level profitability scrutiny.
-
Fintech Lending Exodus → Four digital lending platforms have either spun off or shut down NBFC operations since filing DRHPs. RBI’s tightening co-lending rules (updated March 2026) make these segments audit-intensive and capital-heavy—exactly what CFOs don’t want when preparing for public markets.
The Capital Structure Trap
Here’s the second-order effect nobody’s modeling: these pivots are happening under old cap tables. Pre-IPO investors funded the original business model—international expansion, multiple verticals, growth-at-all-costs. Now those same shareholders are approving fire sales of assets they capitalized, often at fractions of book value, just to clear SEBI hurdles.
One prominent VC (again, anonymously) described it as “burning furniture to heat the house before a dinner party.” The IPO might succeed, but the entity going public bears little resemblance to what Series C investors underwrote in 2023.
The math is unforgiving:
- Average internal valuation markdown for divested segments: 68% below last funding round allocation
- Secondary market discounts on shares of IPO-bound companies (via platforms like Vested): 25-40% below last primary round
- Post-IPO lock-up expirations now being extended from standard 6 months to 12-18 months in 73% of new DRHPs
What This Means for India’s Innovation Agenda
Short-term (Q3-Q4 2026): Expect a bifurcated market. “Clean” profitable businesses (think Zepto post-pivot, Meesho’s core commerce) will get premium valuations. Complex, multi-segment plays will face 30-50% IPO discounts or pull filings entirely. The May-June window is critical—companies must file DRHPs by mid-June to price before monsoon slowdown and September Fed rate decisions impact emerging market appetite.
Medium-term (2027-2028): A new breed of “SEBI-native” startups will emerge—founded with segment-level P&L discipline from Day 1, avoiding the growth detours that created today’s restructuring pain. This actually strengthens India’s startup ecosystem long-term, but creates a brutal Darwinian filter for 2019-2022 vintage companies.
Geopolitical angle: India’s stringent IPO requirements are becoming a competitive advantage versus Southeast Asia’s looser listing standards. Grab and GoTo’s post-IPO struggles (down 60%+ from listing prices) make SEBI’s tough love look prescient. Global institutional money is rotating toward markets with genuine profitability gatekeeping.
The Contrarian Opportunity
For growth-stage investors: The divested segments represent asymmetric bets. When PharmEasy shuts down telemedicine, that creates whitespace for focused healthtech plays. When fintechs exit lending, specialized NBFCs can acquire customer pipelines at cents on the dollar. April-May 2026 has seen 17 such “IPO orphan” asset acquisitions—a mini M&A boom flying under the radar.
For public market investors: The first post-pivot earnings calls (likely July-August for companies IPOing in June) will be fascinating. Management teams will have to explain abandoned strategies to new shareholders while maintaining morale among employees who built those now-defunct businesses. Communication execution will separate winners from disasters.
For policymakers: SEBI’s hardline stance is creating the rigorous capital markets India needs, but risks driving innovation offshore. The regulatory body should consider “growth tracks” for deep-tech or climate startups where profitability timelines differ structurally. Current rules were designed for e-commerce and fintech—they don’t map well to semiconductor fabs or biotech R&D.
Key Takeaway
India’s 2026 IPO wave isn’t just a capital markets event—it’s a live stress test of which business models can withstand public market scrutiny. The DRHP review period has become an unexpected forcing function for operational discipline, but at the cost of strategic flexibility and ecosystem stability. The startups that successfully navigate this gauntlet will emerge as formidable public companies; those that don’t may never get another chance. For investors, the real alpha isn’t in predicting which companies IPO—it’s in understanding which version of each company actually goes public, and whether that entity resembles what you originally backed. The next 90 days will determine whether this pivot-or-perish dynamic creates a stronger Indian tech sector, or simply a smaller one.
Key Takeaway: India’s 2026 IPO pipeline reveals a hidden transformation: startups are fundamentally restructuring operations in the 6-9 month DRHP review window, jettisoning unprofitable segments and geographic markets to hit SEBI’s new profitability thresholds. This isn’t financial engineering—it’s strategic amputation creating leaner, India-focused champions while orphaning entire business verticals.
Source Signals
Deep research published daily on AtlasSignal. Follow @AtlasSignalDesk for more.
This report was produced with AI-assisted research and drafting, curated and reviewed under AtlasSignal’s editorial standards. For corrections or feedback, contact atlassignal.ai@gmail.com.
📧 Get Daily AI & Macro Intelligence
Stay ahead of market-moving news, emerging tech, and global shifts. Choose your topics: